TriSalus Life Sciences, Inc. (TLSI) News
Follow TriSalus Life Sciences, Inc. (TLSI) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
H
Full Transcript: TriSalus Life Sciences Q2 2026 Earnings Call
TriSalus Life Sciences (NASDAQ: TLSI ) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. APIs provide real-time access to earni
LIVE | Oct 12, 2026, 09:38 AM UTC
L
Weekly Recap: FDA 510(k) clearance for TriNav Advance and TLSI stock rally
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) jumped about 6% after FDA 510(k) clearance for TriNav Advance, which expands PEDD use to small distal vessels and more embolizations, with a limited market release planned in co
REGULATION | Sep 28, 2026, 11:06 AM UTC
H
Crude Oil Gains 1%; Cintas Earnings Top Views
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on Wednesday. The Dow traded down 0.52% to 51,588.15 while the NASDAQ dipped 1.10% to 26,943.90. The S&P 500 also fell, drop
LIVE | Sep 23, 2026, 06:08 PM UTC
L
TriSalus Life Sciences Price Target Raised to $12.00/Share From $11.00 by HC Wainwright & Co.
Ratings actions from Benzinga
NEWS | Sep 23, 2026, 10:54 AM UTC
L
HC Wainwright & Co. maintains Buy rating on TriSalus Life Sciences, $12 price target
HC Wainwright & Co. maintained their Buy rating on TriSalus Life Sciences's stock with a price target of $12.00.The price target implies an upside of 143.4% from the Sep 22 close of $4.93.Key takeaways from the analyst n
REGULATION | Sep 23, 2026, 10:43 AM UTC
M
TriSalus Life Sciences secures FDA 510(k) clearance for device
TriSalus Life Sciences said it received FDA 510(k) clearance for a new pressure-enabled drug delivery device; TLSI shares surged 26% to $6.21 after Tuesday’s close.
REGULATION | Sep 22, 2026, 09:24 PM UTC
L
TLSI: Innovative tumor therapy delivery, rapid growth, and new product launches drive future outlook
The company is driving innovation in solid tumor therapy with a unique catheter technology, expanding its sales force, and targeting new clinical indications. Strong revenue growth, improving margins, and a robust cash p
EARNINGS | Sep 14, 2026, 09:48 PM UTC
L
TLSI: Innovative tumor drug delivery drives rapid growth, with new products and clinical data set to expand market share
The company is driving innovation in tumor drug delivery with a unique catheter technology, expanding rapidly in the liver embolization market, and targeting new indications. Financial performance is strong, with robust
NEWS | Sep 14, 2026, 09:36 PM UTC
L
TriSalus Life Sciences initiated at buy by HC Wainwright
HC Wainwright & Co. initiated coverage on TriSalus Life Sciences with a buy rating.
EQUITY | Sep 09, 2026, 10:22 AM UTC
L
TriSalus Life Sciences Affirms FY2026 Sales Guidance of $54.000M-$57.000M vs $52.396M Est
TriSalus Life Sciences (NASDAQ: TLSI ) affirms FY2026 sales outlook from $54.000 million-$57.000 million to $54.000 million-$57.000 million vs $52.396 million estimate.
EARNINGS | Aug 06, 2026, 08:13 PM UTC